Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers

Pancreatic cancer is an increasing cause of cancer related death worldwide. KRAS is the dominant oncogene in this cancer type and molecular rationale would indicate, that inhibitors of the downstream target MEK could be appropriate targeted agents, but clinical trials have failed so far to achieve s...

Descripción completa

Detalles Bibliográficos
Autores principales: Brauswetter, Diána, Gurbi, Bianka, Varga, Attila, Várkondi, Edit, Schwab, Richárd, Bánhegyi, Gábor, Fábián, Orsolya, Kéri, György, Vályi-Nagy, István, Peták, István
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5619833/
https://www.ncbi.nlm.nih.gov/pubmed/28957417
http://dx.doi.org/10.1371/journal.pone.0185687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5619833/
https://www.ncbi.nlm.nih.gov/pubmed/28957417
http://dx.doi.org/10.1371/journal.pone.0185687

Ejemplares similares